Abvc Biopharma, Inc.
ABVC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173313
No open-market purchases or sales by Abvc Biopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.72M in total; no superinvestor holds it.
Other share classesECOC
Q2 2024 vs. Q1 2024
How the institutions holding Abvc Biopharma, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 8 | 11 | +3 |
| Shares | 254.5K | 220.4K | −34.1K (−13.4%) |
| Value | $332.6K | $170.6K | −$162.1K (−48.7%) |
New holders (5)
Institutions that held Abvc Biopharma, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Avantax Planning Partners, Inc. | 39,000 | $30.2K | 0.00% |
| Citadel Advisors LLC | 25,212 | $19.5K | 0.00% |
| Northern Trust Corp | 19,135 | $14.8K | 0.00% |
| XTX Topco Ltd | 18,944 | $14.7K | 0.00% |
| State Street Corp | 12,900 | $9.98K | 0.00% |
Sold out (2)
Institutions that held Abvc Biopharma, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Chase Investment Counsel Corp | 178,377 | $233.0K |
| Wells Fargo & Company | 48 | $63 |